

## REQUEST FOR APPLICATIONS (RFA)

# MSCRF Validation Program

### INTRODUCTION:

Stem cell research offers extraordinary promise for new medical therapies and a better understanding of debilitating human diseases, injuries and conditions. The development of new medical strategies for the prevention, diagnosis, treatment and cure of human diseases, injuries and conditions through human stem cell research is a high priority for the State of Maryland.

### FUNDING OBJECTIVES

The Maryland Stem Cell Research Fund (MSCRF) Validation Program was created to foster the transition of promising stem cell technologies having significant commercial potential from Universities and research labs where they were discovered, to the commercial sector, where they can be developed into products and services that meet identified market needs. Specifically, it is the intent of the Validation Program to foster the commercialization of such technologies through technology validation, market assessment, and the creation of University start-up companies in Maryland. It is also the intent of the Program to foster collaborations between various schools, departments, and institutions within research organizations in the State.

### ELIGIBILITY INFORMATION

To be eligible for the Validation Program, the applicant must be a faculty member at a Maryland based university or research institute (not a Federal Lab). Applications must be directed to the validation of a technology or group of technologies: (i) owned by a University or a research institute; (ii) disclosed to a technology transfer office (TTO); (iii) for which there exists appropriate intellectual property protection; and (iv) the technology is not licensed to any entity.

### AWARD INFORMATION

#### AVAILABLE FUNDS

The MSCRF is currently budgeted to commit up to \$8.2 million, in aggregate, in FY 2019 to fund Grants under all of its RFAs. The number of Grants awarded will depend upon the quality, size and mix of Applications received.

#### AWARD SIZE, DURATION & TERMS

Subject to meeting the Program requirements, an award not to exceed \$200,000 may be made for a project. Funded Projects must be completed within 18 months of the date of execution of the award. **Applicants should not expect approvals for any project extensions and should plan accordingly.**

The Program will allow Universities to include facilities and administrative charges (i.e., indirect charges) of up to 15% of the overall budget. Max amount per Award is \$230,000.

**Project funding will be subject to the successful completion of a number of proposed project milestones. Applicants should be aware that project funding could be terminated at any point during the project if early project data suggests that the technology will not be sufficient for the intended commercial application or if the project is not reasonably progressing as originally proposed.**

#### **OVERVIEW AND PROGRAM DESCRIPTION:**

##### **Technology Validation**

“Technology Validation” builds on preliminary data demonstrating the utility of a Technology for a specific commercial application. **This is not new research.** The Technology must have appropriate intellectual property protection secured by the applicant institution.

Up to \$10,000 of the Technology Validation budget may be allocated by a Qualifying University TTO to pay for patent expenses related to the Technology, which are incurred during the Validation Program.

A final report will be the deliverable for this component of the Validation Program.

#### **BEYOND VALIDATION PROGRAM FUNDING**

The goal of the MSCRF Programs is to move technologies from the successful validation stage, to the commercial sector via a license to a (a) University Start-up company located in Maryland or (b) another company outside of the state. To this end, investigators who have successfully achieved specified Validation Program project milestones and submitted their final report are encouraged to work toward the creation of a start-up company and to have that company apply for funding for Early-stage Development by submitting a Commercialization Program Application.

Validation Program Awards will be made in the form of a grant.

#### **CONTENT & FORMAT OF APPLICATION**

All Sections of the Application must be submitted through the [TEDCO on line submission system](#). The document must be formatted using point size 12 Arial font, with margins no smaller than one-half (0.5) inch on all sides. Uploaded file must be limited to 5 (five) megabytes (MB).

**University applicants must obtain approval from their research/grants administration office before submitting an application, a letter from the office is only required for the mailed hard copy.**

#### **APPLICATION COMPONENTS**

The intent of the application is to provide enough information so a group of reviewers can sufficiently evaluate the commercialization potential of a Technology and the value of the proposed project in advancing the Technology toward commercialization.

**Validation Program Applications** must include all of the following sections and address *EACH* of the criteria bulleted under the sections (Sections B through E should be limited to 10 pages):

- A. **Header/Applicant Information (Cover page).** The Applicant must include:
- The name of the University/Research Lab that is applying for funding and owns the subject Technology.
  - Title of the Project.
  - Short (300 words) abstract.
  - The name of a principal investigator who will be responsible for the project.
  - The total amount of funding requested including indirect costs.
- B. **Technology Description, Status, and Intellectual Property.**
- A detailed description of the associated Technology should be provided. The description should focus on how the Technology is unique/novel in its approach to solve an important problem relative to other approaches in the scientific literature and other products.
  - Describe the status of the Technology's development – describe the studies completed and the conclusions derived (to support how unique your technology/idea is; can be previously published data).
  - Any preliminary data or other results supporting that the Technology is likely to work as predicted should be included.
  - Describe the intellectual property secured for the Technology and strategies for strengthening the Technology's intellectual property portfolio. Including a brief summary of the intellectual property landscape (e.g., the results of a patent search including a description of the closest prior art) should also be included.
- C. **Application of Technology as a Product/Market Assessment.**
- Describe potential products or services that could be based on the technology.
  - Describe how these products will solve a problem in the market and describe the overall importance of solving that problem.
  - Include a description of the value that these products will bring to customers – cost savings, time savings, convenience, improved outcomes, etc.
  - Outline a general description of the applicant's competitive advantages over competing products and services.
- D. **Commercialization Pathway and Risk Assessment.**
- Provide a detailed overview of the overall steps/milestones needed to commercialize the Technology (during and **beyond** the MSCRF funding) including how long it will take and how much it will cost to achieve each milestone.
  - Describe the general approach and rationale for commercialization – licensing or start-up. In either case, identify potential commercial partners and the level of interest those partners have in the technology, if any (**it is recommended to provide support letters**).
  - The major risks of failure (beyond the proposed MSCRF project, e.g., technology risk, market risk, etc.) should also be described along with the applicant's plans to manage that risk, i.e., what would be done if the proposed commercialization approach was not successful.
- E. **Project Description, Milestones, and Detailed Budget/Justification.**
- Include a detailed summary of the proposed MSCRF project and the anticipated milestones and a clear timeline (**remember, this is not discovery – this is validating your findings and the market**). Indicate which milestones will be completed by the applicant's mid-term presentation (about 9 months into the project) and throughout.
  - A description of the Research Strategy and Design, Data in support of the Proposal (preliminary data if applicable), Significance, Specific Aims, Rationale, Approach and Innovation.

- Describe how each of the milestones leads to a clear demonstration or validation of the technology for the proposed commercial purpose and/or significantly advances the technology along the commercialization pathway. Milestones must be quantifiable and measurable so it will be obvious when they have been successfully, or unsuccessfully, met.
- A detailed budget of the costs required to conduct the project should be provided in the general format provided below.
- A justification for all of the project costs should be provided. Any changes to the approved budget (greater than +/- 10%) must be submitted in writing to TEDCO for approval prior to the completion date.
- International travel is not an eligible expense. Domestic travel will be closely scrutinized and must be justified as critical to the project.

The Technology Validation budget (maximum \$200,000) should be formatted in tabular form, and each line item should be classified into one of the following categories: Personnel – Salaries, Personnel- Fringe benefits, Equipment, Materials & Supplies, Contracts, Other Direct Costs, and Indirect Costs, which should be indicated in the budget.

### **Supplemental Materials (additional 12 pages limit)**

In addition, applications must include the following supplemental materials. These pages are counted as part of the maximum 22 pages total:

- a. A signed letter from the University's technology transfer office indicating their approval of the project, certifying the Technology's disclosure reference number and the status of the intellectual property described in Section 'B.' of the Initial Application.
- b. Recommendation/collaboration letters supporting and justifying the project and aims endpoints.
- c. Biosketches of the team, limited to 2 pages each.
- d. Supporting materials. Do not include information that should be in the 10 page limit of the proposal. References can be included here.

### **Web form Information**

In addition, applications must complete all the web form information in the online system. This information may include bioethics section as well as co-PIs and other information.

Applicants are encouraged to utilize students at business schools and other resources at the various Universities in the development of their applications. Applications should also be developed through a collaboration involving the faculty and the TTO responsible for the subject Technology.

### **Resubmissions**

**Response to Reviewer's Comments.** In the event that an applicant's proposal is initially rejected and the applicant chooses to reapply for Program funding, the applicant must submit a written response to the reviewers' comments including how those comments were addressed in the resubmitted application. The Response to Reviewer's Comments may not exceed one (1) page and is not counted as part of the page count for the resubmitted application.

**Include an *updated* letter from the Qualifying University's technology transfer office** indicating any current activity or updates to tech transfer activities.

## APPLICATION AND SUBMISSION INFORMATION

Application information will be available electronically on the MSCRF Web site (see [www.mscref.org](http://www.mscref.org)).

### **SUBMISSION DEADLINES & REVIEW DATES**

**Application Submission Deadline:** January 17, 2019, by 5:00 p.m.

**Peer Review Date(s):** March 2019

**Commission Review Date(s):** May 2019

**Earliest Anticipated Start Date:** June 2019

### **METHODS OF SUBMISSION**

#### **Grant Application**

PIs, must register in the TEDCO on line submission system at least one month before the Application Submission Deadline. Grant Applications must be submitted through the [TEDCO on line submission system](#) by January 17, 2019, no later than 5:00 p.m.

One signed paper copy of the Application must be submitted by mail to the Maryland Stem Cell Research Fund (see address below). The paper copy of the Application must be postmarked no later than January 21, 2019. All submissions must be received by their respective due dates. Late submissions and hand deliveries will be NOT be reviewed.

Paper copies should be sent to:

**Maryland Stem Cell Research Fund – Validation Program**

**Maryland TEDCO**

**7021 Columbia Gateway Drive, Suite 200**

**Columbia, Maryland 21046**

## REVIEW INFORMATION

### **REVIEW PROCESS:**

All applications for Validation Program awards will be initially reviewed to ensure that they meet the minimum requirements, as specified in this RFA (the “Compliance Review”). Applications not meeting the minimum requirements will be rejected without further consideration and the applicant will be so notified.

A complete submission (all sections) cannot exceed a total of 22 pages or it will be rejected without consideration.

#### **Application Review Process**

Following the Compliance Review, all Applications will be assigned by the MSCRF to a number of reviewers for review and preliminary scoring. All Applications receiving average scores above a threshold determined by the MSCRF will be brought to the full MSCRF Review Committee for discussion and final scoring. MSCRF may bring Applications scoring below the threshold to the Review Meeting under special circumstances, which shall be determined at the sole discretion of the MSCRF. All Applications will be ranked according to their final scores and the top scoring applications will be recommended to the Maryland Stem Cell Research Commission (Commission), which will have the final authority to approve funding. The MSCRF Review Committee will consist of outside of state researchers, and business people.

Each applicant will receive a copy of the reviewer comments and scores at the end of the process, whether the applicant is approved or declined.

#### **REVIEW CRITERIA:**

Applicants will be evaluated on each section of their proposal and the applicant's ability to address each criterion listed in the section. **Consideration will be based on how completely the applicant has provided information requested for the section and how convincingly the applicant has made a case for the opportunity based on the subject Technology.**

Other criteria that will be considered by the reviewers are: the novelty of the Technology and the approach to solving a problem (meeting a market need), the strength of the Technology's competitive advantage (intellectual property position), the likelihood that a University Start-up will be created based on the Technology, the market/commercialization opportunity represented by the project, and the team's ability to carry out the project. Be sure to address the following areas:

-  **Significance:** Does this Project address an important scientific problem, relevant to human stem cells? What is the relationship between the proposed project and the etiology, prevention, diagnosis or treatment of human diseases or conditions? If the aims of the Application are achieved, how will this move you closer to commercial or clinical practice and treatment of human diseases or conditions?
-  **Approach:** Is there adequate preliminary data to support the Validation Project? Are the conceptual or clinical framework, design, methods and analyses adequately developed, well integrated, well-reasoned and appropriate to the aims of the Project? Is relevant literature appropriately referenced? Are anticipated results discussed and justified? Does the Applicant acknowledge potential problem areas and consider alternative tactics? Are the experiments as designed likely to significantly advance the technology?
-  **Translation Potential and Plan:** Does the Application include strong interactions to commercial or clinical components? Is there a clear plan for translating results to the commercial market? Will the Project lead to new medical therapies or test new therapies in patients?
-  **Bioethics:** Does the proposed project use adult, embryonic, iPS or other human stem cell lines? If an existing line is to be used, what are the justifications for that line? If human donors are involved, have they been properly consented? If human subjects are involved, what protections will be in place to ensure their rights and welfare? If animal subjects are to be used, what measures are taken to comply with IACUC guidelines?

#### **SCORING:**

The Scientific Peer Review Committee will review all Applications and rank them based on scientific merit. Similar to the NIH scoring system of 1-9 will be used to rate the overall impact/priority of the proposed research. In this system, "1" indicates the highest impact/priority and "9" indicates the lowest impact/priority. The Commission will then review the ranked Applications and will make the final funding decisions.

After presentation of the preliminary scores and discussion of applications at the MSCRF Review Committee Meeting, applications will receive a final score based on an average of all the overall scores provided by the MSCRF Review Committee Members.

Applications will be ranked by average final score and submitted to the Commission for review and final approval.

## AWARD ADMINISTRATION INFORMATION

### NOTIFICATION

The PI's affiliate organization will be notified electronically when the Application is received. After the TEDCO Board has approved the Commission's recommendations, a formal notification, in the form of a Notice of Award ("NOA"), signed by the MSCRF Executive Director, will be sent via email to successful Applicants.

### CLOSING AND AWARD PAYMENTS:

Once the proper approval for a project has been obtained, Applicants will be asked to execute an agreement and **the Principal Investigator will be asked to immediately start working on the Project**. The agreement will detail the conditions of the award and it will include an agreed upon number of mid-term and final milestones for each project and the dates that Mid-term and final project reports (as described below) are due.

All PI's are expected to present in person for the mid-term review. (Details will be sent approximately one month prior to the mid-term of the project, based on the date of the executed agreement.) All PI's should know the start date (the signed agreement date) of their MSCRF Project, as well as the end date.

Award payments for Validation projects will be made as follows: 25% following execution of the grant agreement, 50% upon submission and approval of a Mid-term Report and the successful completion of approved milestones, and 25% upon submission and approval of a Final Report.

In all cases, any unused funds must be returned to TEDCO serving in its capacity as the administrator of the Program.

### POST AWARD REPORTING

Validation Program awardees must submit the following reports to the MSCRF Program including:

- a. **Award Manager Meeting** – each applicant is required to meet with the MSCRF Award Manager at least once, prior to the mid-term. This is to assist each awardee in understanding and meeting expectations for the program. This is also an opportunity for the awardee to share feedback, discuss ideas and ask for additional assistance.
- b. **Mid-Project Reports**, (*in-person* PowerPoint presentation at TEDCO's offices) which must include a description of project activities and results to date, the progress toward meeting mid-term milestones, an accounting of expenditures charged to the award, and details on the proposed Commercialization Plan and budget;
- c. **Final Report** - Within forty-five (45) days after the end of the overall Grant period, PIs must file their Final Reports, describing the research conducted and the results of this research. This Final Report shall include:
  - i. **Project report**, which must provide an overview of all activities undertaken during the course of the funded project, a description of the results of the project, the impact on commercialization, the success with achieving the proposed milestones, a full accounting of all expenditures charged to the award, and suggestions for ways to improve the Program;
  - ii. **Commercialization Planning** Includes conducting a commercial opportunity and risk assessment for a Technology and developing and drafting a detailed commercialization and go-to-market plan

(a specific deliverable for the Validation Program) that includes a plan for the specific steps required to complete the development of a product, its manufacture, regulatory approvals, and its execution. The Commercialization Plan should include:

- A clear market assessment and marketing strategy;
- The team, and their biographical information;
- A viable revenue model; and
- A strategy for financing the plan.

TEDCO recognizes the challenges associated with developing a commercialization strategy for an early-stage technology and understands that any such strategy is likely to change during the course of development of a commercial product. Nevertheless, as a commercialization program, the goal of MSCRF is to ensure that there is at least one viable pathway toward commercialization for a technology and that such a pathway has been carefully considered and can be clearly described by the applicant.

**The execution of any subcontracts and joint arrangements included as part of an application are ultimately the responsibility of the PI. Each entity involved in the proposed project set forth in the submitted application is expected to meet the timelines and milestones, as submitted by the PI, who will be held accountable as part of the mid-term and final report review.**

- d. **Symposium presentation** - The MSCRF will conduct an in-State Annual Symposium to report to the scientific community and the public the progress of the MSCRF program. All PIs must present, orally or in poster format, their on-going or completed MSCRF-funded research at each Annual Symposium, during and immediately following their Grant period.

#### **AGENCY CONTACTS**

Questions about this RFA must be submitted by email to: [mscrinfo@tedco.md](mailto:mscrinfo@tedco.md). Telephone inquiries will not be accepted.